Brief: Phio Pharmaceuticals Positive Safety Monitoring Committee Recommendation To Continue To Third Dose Cohort In Its Clinical Study Of Ph-762
19/12/2024 14:15
Dec 19 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS: POSITIVE SAFETY MONITORING COMMITTEE
RECOMMENDATION TO CONTINUE TO THIRD DOSE COHORT IN ITS CLINICAL
STUDY OF PH-762
* INTRATUMORAL INJECTIONS HAVE BEEN WELL TOLERATED
* NO DOSE-LIMITING TOXICITIES, OR SERIOUS ADVERSE EVENTS IN
PARTICIPANTS RECEIVING INTRATUMORAL PH-762
Source text: ID:n0001683168-24-008833
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing